# US 2019/0292251 A1 · Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0292251 A1
- Document ID: US20190292251A1
- Status: Published application
- Kind: A1
- Application number: 16/177,792
- Filed: 2018-11-01
- Published: 2019-09-26
- Earliest claimed: 2014-06-20
- Assignees: AVEO Pharmaceuticals, Inc.
- Applicants: AVEO Pharmaceuticals, Inc.
- Inventors: Jeno Gyuris; Lorena Lerner
- Web page: https://patentgrep.com/patent/US20190292251A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides methods and compositions of treating a subject having a cardiac-related disorder such as congestive or chronic heart failure (CHF), cardiac hypertrophy, cardiac hypotrophy, and other cardiac myopathies/dystrophies. The methods comprise administering an effective amount of a composition that modulates, for example, reduces or inhibits, GDF15 activity in the subject.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

A method of treating a subject having a cardiac disorder or dysfunction, the method comprising administering an effective amount of a composition comprising a GDF15 modulator thereby to ameliorate a symptom of the cardiac disorder or dysfunction.

### Claim 4 (depends on 3)

The method of claim 3, wherein the subject has elevated GDF15 activity in a body fluid.

### Claim 5

A method of reducing or reversing cardiac hypotrophy in a subject exhibiting one or more symptoms of congestive heart failure, the method comprising administering an effective amount of a composition comprising a GDF15 modulator, wherein the composition ameliorates at least one symptom of cardiac hypotrophy in the subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein the subject has elevated GDF15 activity in a body fluid.

### Claim 7

A method of treating or preventing congestive heart failure (CHF) in a subject in need thereof, the method comprising administering an effective amount of a composition that reduces or inhibits a GDF15 activity in the subject, thereby to treat or prevent CHF in the subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein the subject has elevated GDF15 activity in a body fluid.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of any one of claim 1, wherein the subject exhibits a peak VO2 of less than less than 14 mL/kg/min.

### Claim 12 (depends on 1)

The method of any one of claim 1, wherein the subject exhibits an LVEF of less than 40%.

### Claim 13 (depends on 1)

The method of any one of claim 1, wherein the subject exhibits BNP levels in excess of 100 pg/ml.

### Claim 14 (depends on 1)

The method of any one of claim 1, wherein the subject exhibits serum cardiac troponin I (cTnI) levels in excess of 1.5 ng/mL.

### Claim 15 (depends on 1)

The method of any one of claim 1, wherein the subject has been diagnosed as having congestive heart failure.

### Claim 16 (depends on 1)

The method of any one of claim 1, wherein the GDF15 modulator reduces or inhibits GDF15 activity in the subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the GDF15 modulator binds GDF15.

### Claim 18 (depends on 17)

The method of claim 17, wherein the GDF15 modulator is an anti-GDF15 antibody.

### Claim 19 (depends on 18)

The method of claim 18, wherein the antibody is humanized or human.

### Claim 20 (depends on 1)

The method of claim 1, wherein the subject exhibits above normal levels of a marker selected from the group consisting of cardiac troponin I, cardiac troponin T, brain natriuretic protein (BNP), N-terminal peptides derived from BNP (NT-proBNP), and cardiac fatty acid binding protein (cFABP).

### Claim 21 (depends on 6)

The method of claim 6, wherein the body fluid is plasma or serum.

### Claim 22 (depends on 18)

The method of claim 18, wherein the anti-GDF15 antibody is selected from:
a) an antibody comprising the heavy chain sequence of SEQ ID NO:47 and the light chain sequence of SEQ ID NO:30; and
b) an antibody comprising a heavy chain CDRH1 sequence of SEQ ID NO:1, a heavy chain CDH2 sequence of SEQ ID NO: 7, and a heavy chain CDRH3 sequence of SEQ ID NO:13; and a light chain CDRL1 sequence of SEQ ID NO:16, a light chain CDRL2 sequence of SEQ ID NO:18, and a light chain CDRL3 sequence of SEQ ID NO:22.
